FGF2 and asthma: have reported that BM-MSC-EXO carrying miR-221-3p inhibit the expression of fibroblast growth factor 2 (FGF2) and the ERK1/2 signaling pathway, resulting in reduced proliferation and migration of ASMCs, decreased extracellular matrix (ECM) deposition, and alleviation of airway remodeling in OVA-induced asthma mice [121].